Abstract: Described herein is a method for amplifying a target nucleic acid sequence ta-tC-tV-tC?-tn? comprising a first amplification using a first primer pair with sequence ma-K-pC and ma-K?-pC?, and a subsequent second amplification using a second primer pair with sequence aL-aP-aK and aL?-aP?-aK?, wherein pC is the same sequence as sequence element tC. pC and pC? are 8 to 40 nucleotides in length, K comprises a 3?-terminal sequence k1-k2-s, s is a mismatch sequences preventing PCR bias, ak is the same sequence as sequence element k1, aP-aK hybridize to a contiguous sequence on sequence element ma-K, k1 is 2 to 9 nucleotides in length, aL and aL? can be any sequence, and tV is a variable region within the target nucleic acid sequence. Also described are collections of primer sets for use in the method of the invention.

Abstract: The invention relates to a method for amplifying a target nucleic acid sequence tn-tC-tV-tC?-tn? comprising a first amplification using a first primer pair with sequence ma-K-pC and ma-K?-pC?, and a subsequent second amplification using a second primer pair with sequence aL-aP-aK and aL?-aP?-aK?, wherein pC is the same sequence as sequence element tC. pC and pC? are 8 to 40 nucleotides in length, K comprises a 3?-terminal sequence k1-k2-s, s is a mismatch sequences preventing PCR bias, ak is the same sequence as sequence element k1, aP-aK hybridize to a contiguous sequence on sequence element ma-K, k1 is 2 to 9 nucleotides in length, aL and aL? can be any sequence, and tV is a variable region within said target nucleic acid sequence. The invention further relates to collections of primer sets for use in the method of the invention.

Abstract: The invention refers to a fully human miniantibody (scFv), called Erbicin, specific for the receptor ErbB2, with a pharmacological, in particular antitumour, activity. It has been obtained from a larger fagmidic library (Griffin 1.) (19) of human synthetic scFv by panning (affinity selection on antigen) carried out on live cells that express various levels of ErbB2. The invention relates also to the DNA and aniino acid sequences of said antibody, to the procedure for isolating it, to its use in therapy.